Clinical Features and Multivariate Cox Regression Prognostic Analysis of Operable Breast Cancer: A Report of 2 342 Cases
-
摘要:
目的 分析可手术的浸润性乳腺癌患者临床及病理学资料, 探讨其预后的影响因素。 方法 收集2002年1月至2004年12月间天津医科大学附属肿瘤医院收治的2 342例可手术的浸润性乳腺癌患者的临床病理学资料, 回顾性分析其临床病理学特征、复发转移及生存情况, 并利用诺丁汉预后指数(Nottingham Prognostic Index, NPI)进行预后生存分析。 结果 2342例乳腺癌患者平均年龄为51.56岁。临床分期Ⅰ、Ⅱ、Ⅲ期分别为571例(24.38%), 1143例(48.8%), 628例(26.82%)。NPI评分低、中、高危组分别为521例(22.25%)、1151例(49.15%)、670例(28.6%)。ER阳性1271例(54.3%), 阴性1071例(45.7%)。PR阳性1698例(72.5%), 阴性644例(27.5%)。C-erbB-2阳性787例(33.6%), 阴性1 555例(66.4%)。单因素分析结果显示, 影响患者5年无瘤生存期(disease-free survival, DFS)及总生存期(overall survival, OS)的因素包括: 临床分期、肿瘤大小、淋巴结状态、组织学分级、家族史、NPI评分、ER、PR及C-erbB-2状态。另外年龄也是影响5年DFS的因素之一。多因素分析结果显示, 影响5年DFS及OS的因素包括: NPI评分、ER、PR及C-erbB-2。 结论 本研究通过分析大宗可手术的浸润性乳腺癌患者临床病理学资料, 证实NPI评分、ER、PR及C-erbB-2为判断浸润性乳腺癌预后较好的临床病理学指标。 Abstract:Objective The present paper aims to analyze the clinicopathologic data of patients with operable infiltrating breast cancer and investigates the factors that influence breast cancer prognosis. Methods The clinical data of 2342 cases with operable infiltrating breast cancer treated in the Medical Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China from January 2002 to December 2004 were collected.The clinicopathologic characteristics of the cancer, recurrence and metastasis, and patient survival rate were retrospectively analyzed.The Nottingham prognostic index(NPI) was used to analyze their prognostic survivals. Results The average age of patients was 51.56 years.The cases at clinical stagesⅠ, Ⅱ, andⅢaccounted for 24.38%(571), 48.8%(1143), and 26.82%(628) of patients, respectively.The cases with an NPI score of low, average, and high-risk recurrence respectively accounted for 22.25%(521), 49.15%(1151), and 28.6%(670) of patients.The estrogen receptor(ER) positive, progesterone receptor(PR) positive, and C-erbB-2 over-expression of the tumors were 54.3%(1271), 72.5%(1698), and 33.6% (787), respectively.The univariate analysis revealed that the prognostic factors affecting the 5-year disease-free survival(DFS) and overall survival(OS) included clinical staging, tumor size, lymph node status, histological grading, family history, NPI, ER, PR, and C-erbB-2 status.Moreover, age also affected the 5-year DFS.The multivariate Cox regression analysis showed that the prognostic factors that influence DFS and OS were the NPI, ER, PR, and C-erbB-2 states. Conclusion Analysis of the clinicopathologic data of a large number of cases with operable breast cancer confirmed that NPI, ER, PR, and C-erbB-2 status were preferable indicators for breast cancer prognosis. -
Key words:
- Breast cancer /
- NPI /
- Prognosis
-
表 1 2 342例乳腺癌术后患者的一般资料 例（%）
Table 1. General data of postoperative breast cancer patients
表 2 影响各期患者预后的单因素分析 %
Table 2. Univariate analysis for the prognosis of patients with different stages of breast cancer
表 3 影响乳腺癌患者5年DFS的多因素分析
Table 3. Multivariate Cox regression analysis of the prognostic factors affecting the 5-year DFS of breast cancer patients
表 4 影响乳腺癌患者5年OS的多因素分析
Table 4. Multivariate Cox regression analysis of the prognostic factors affecting the 5-year OS of breast cancer patients
-
[1] Leong SP, Shen ZZ, Liu TJ, et al. Is Breast Cancer the Same Disease in Asian and Western Countries[J]? World J Surg, 2010, 34 (10): 2308-2324. [2] Munirah MA, Siti-Aishah MA, Reena MZ, et al. Identification of different subtypes of breast cancer using tissue microarray[J]. Rom J Morphol Embryol, 2011, 52(2): 669-677. http://www.rjme.ro/RJME/resources/files/520211669677.pdf [3] Cutuli B, Cottu PH, Guastalla JP, et al. A French national survey on infiltrating breast cancer: analysis of clinico-pathological features and treatment modalities in 1159 patients[J]. Breast Cancer Res Treat, 2006, 95(1): 55-64. doi: 10.1007/s10549-005-9034-6 [4] Li CI, Weiss NS, Stanford JL, et al. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle -aged women[J]. Cancer, 2000, 88(11): 2570-2577. doi: 10.1002/1097-0142(20000601)88:11<2570::AID-CNCR20>3.0.CO;2-O [5] Su Y, Zheng Y, Zheng W, et al. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study[J]. BMC Cancer, 2011, 11(1): 292. doi: 10.1186/1471-2407-11-292 [6] Yin W, Jiang Y, Shen Z, et al. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials[J]. PLoS One, 2011, 6 (6): e21030. doi: 10.1371/journal.pone.0021030 [7] Al-azawi D, Leong S, Wong L, et al. HER-2 positive and p53 negative breast cancers are associated with poor prognosis[J]. Cancer Invest, 2011, 29(5): 365-369. doi: 10.3109/07357907.2011.584586 [8] Wiseman SM, Makretsov N, Nielsen TO, et al. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival[J]. Cancer, 2005, 103(9): 1770-1777. doi: 10.1002/cncr.20970 [9] Early Breast Cancer Trialist's Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials[J]. Lancet, 2000, 355(9217): 1757-1770. doi: 10.1016/S0140-6736(00)02263-7 [10] Liu MT, Huang WT, Wang AY, et al. Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index[J]. Support Care Cancer, 2010, 18(12): 1553-1564. doi: 10.1007/s00520-009-0778-0 [11] Lee AH, Ellis IO. The Nottingham prognostic index for invasive carcinoma of the breast[J]. Pathol Oncol Res. 2008, 14(2): 113-115. [12] Van Belle V, Van Calster B, Brouckaert O, et al. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis[J]. J Clin Oncol, 2010, 28(27): 4129-4134. doi: 10.1200/JCO.2009.26.4200 -
点击查看大图
表(4)
计量
- 文章访问数: 42
- HTML全文浏览量: 0
- PDF下载量: 0
- 被引次数: 0
下载:
